Existing investor AstraZeneca was among the investors that took part in the placement, which lifted the cancer drug developer's overall financing to $255m.
Switzerland-based oncology treatment developer ADC Therapeutics (ADCT) completed a $105m private placement yesterday featuring AstraZeneca.
The placement also included life sciences-focused private equity firm Auven Therapeutics, Wild Family Office and undisclosed new and existing investors.
Founded by Auven in 2012, ADCT is working on antibody drug conjugates that will form the basis for therapeutics that will fight major cancers. It has clinical and preclinical programs in place targeting haematological malignancies and solid tumours.
ADCT will use the financing to advance…
